TrialThoracic cancer2021

Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.

Jianhua Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.